The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 52-60

  Kirschbaum, Mark H ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Carcinoma; Chemoprevention; Oncogene; Signal transduction; Tyrosine kinase

Indexed keywords

PROTEIN TYROSINE KINASE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOTOXIN; NEU DIFFERENTIATION FACTOR;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOMA; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; GENE THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECT; EPITHELIUM; GENETICS; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY;

ENZYME INHIBITORS; EPITHELIUM; GENE THERAPY; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS; NEUREGULINS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 0033654451     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<52::AID-JCB10>3.0.CO;2-X     Document Type: Review

References (23)

1. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. 1992. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974-979.
2. Alvarez RD, Curiel DT. 1997. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-Erbb-2 single chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther 8:229-242.
3. Anan K, Morisaki T, Katano M, Ikubo A, Tsukahara Y, Kojima M, Uchiyama A, Kuroki S, Torisu M, Tanaka M. 1998. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential. Eur J Surg Oncol 24:28-33.
4. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D. 1998. neu/ erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349.
5. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. 1996. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88:123-125.
6. Bargmann CI, Hung MC, Weinberg RA. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see comments]. J Clin Oncol 14:737-744.
8. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. 1992. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 89:5867-5871.
9. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257.
10. Ben-Baruch N, Alroy I, Yarden Y. 1998. Developmental and physiologic roles of ErbB receptors and their ligands in mammals. In: Dickson RB and Saloman DS, editors. Hormones and growth factors in development and neoplasia. New York: Wiley-Liss.
11. Bray D. 1990. Intracellular signaling as a parallel distributed process. J Theor Biol 143:215-231.
12. Burden S, Yarden Y. 1997. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18:847-855.
13. Burke HE, Hoang A, Iglehart JD, Marks JR. 1998. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82:874-877.
14. Curnow RT. 1997. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45:210-215.
15. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. 1997. High-liter HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363-3367.
16. Fabian CJ, Kamel S, Zalles C, Kimler BF. 1996. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem Suppl 25:112-122.
17. Fan Z, Mendelsohn J. 1998. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol 10:67-73.
18. Gasparini G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N. 1994. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat 29:59-71.
19. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. 1997. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272-3280.
20. Kinzler WK, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
21. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. 1997. A subclass of tumor-inhibitory monoclonal antibodies to erbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-2109.
22. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G. 1992. The erbB-3 gene in human pancreatic cancer. J Pathol 168:269-273.
23. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. 1995. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405-1410.